Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
Boston, Massachusetts, United States, 02111
- Floating Hospital For Children at Tufts Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female subjects, newborn to age 3 months
- Have a diagnosis of cystic fibrosis (Diagnosis of CF will be based on either a positive sweat chloride of >60 mEq/L or the identification of two detectable mutations associated with CF
- Parent/guardian plans to have follow-up care for approximately one year at designated CF clinic
- Parent/guardian provides informed consent to participate in the study
Exclusion Criteria:
- Contraindications for obtaining oropharyngeal swabs
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Throat Swab
Infants who have been diagnosed with cystic fibrosis
|
Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To characterize the microbial ecology and changes in bacterial diversity of the oropharynx in a cohort of children with CF during the first year of life using 16S rRNA sequence analysis
Time Frame: 6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
|
6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
|
|
To describe the clinical variables that may be associated with changes in microbial ecology in children with cystic fibrosis over the first year of life
Time Frame: 6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
|
6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
|
|
To explore changes in the microbial ecology of the oropharynx in conjunction with Staphylococcus aureus colonization in children with CF
Time Frame: 6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
|
6-8 weeks of age, 3 months, 6 months, 9 months, and 12 months of age
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 8851
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
NCT03273959UnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With Exacerbation
-
NCT07223255RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Gastrointestinal Disease
-
NCT07616375RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07245407RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07289464RecruitingNon-cystic Fibrosis Bronchiectasis
-
NCT07484607RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary Exacerbation
-
NCT03939065TerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children
-
NCT04602468Active, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver Disease
-
NCT06084468Active, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease
-
NCT06940531RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary Exacerbation
Clinical Trials on Throat Swab
-
NCT04557046Active, not recruiting
-
NCT04405466Completed
-
NCT01592799Completed
-
NCT02623985Completed
-
NCT07106944Not yet recruitingCarriage of ESBL-positive Escherichia Coli | Carriage of ESBL-positive Klebsiella Pneumoniae
-
NCT05959408RecruitingMen Who Have Sex With Men
-
NCT02352389Completed
-
NCT06418516Not yet recruitingHead and Neck Cancer | Esophageal Cancer | Squamous Cell Carcinoma